Suven Life Sciences will be presenting several exciting new results and data presentation from their portfolio of investigational neuroscience new chemical entities (NCEs) at Alzheimer's Association International Conference (AAIC) being held in Vancouver, Canada from July 14 to 19, 2012.
AAIC is the world's largest conference of its kind, bringing together researchers from around the world to report and discuss groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders.
Alzheimer's disease is one of the scourges of modern day health care which is the largest and fastest growing unmet medical need and Suven is in the forefront of developing a drug for the treatment of this debilitating disease. Alzheimer's is a dementia that causes problems with memory, thinking and behavior. Alzheimer's is not just a memory loss as everyone thinks but Alzheimer's kills.
Suven has excellent portfolio of new molecules through four mechanisms of action using 5-HT6, 5-HT4, H3 and Neuronal Nicotinic acetylcholine receptors for the treatment of cognitive impairment in Alzheimer's disease symptomatically but also possibly useful in reducing the disease progression. Suven scientists are presenting pre-clinical and clinical data on these molecule and other NCEs on cognitive impairment and memory related disorders.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1688.75 |
Dr. Reddys Lab | 1108.55 |
Cipla | 1433.45 |
Lupin | 1984.10 |
Zydus Lifesciences | 860.95 |
View more.. |